PRVEP | All patients | Control values | p-values | 95% CI | Group 1a | Control values | p-values | 95% CI | ||
---|---|---|---|---|---|---|---|---|---|---|
P100-Da 60 R Lob | Amplitude (μV) | RE | 8.82 ± 4.33 | 7.29 ± 1.59 | 0.2852 | – | 5.05 ± 1.03 | 7.29 ± 1.59 | 0.0011 | [1.020 to 3.450] |
LE | 8.45 ± 4.36 | 0.4193 | – | |||||||
Latency (ms) | RE | 115.17 ± 10.21 | 112.6 ± 7.19 | 0.4684 | – | 130.9 ± 8.17 | 112.6 ± 7.19 | < 0.0001 | [−25,36 to − 11,24] | |
LE | 118.06 ± 9.71 | 0.1127 | – | |||||||
P100-Da 60 L Lob | Amplitude (μV) | RE | 8.88 ± 7.44 | 6.33 ± 2.40 | 0.2974 | – | 5.15 ± 1.02 | 6.33 ± 2.40 | 0.1538 | – |
LE | 8 ± 3.65 | 0.1872 | – | |||||||
Latency (ms) | RE | 114 ± 9.24 | 111.2 ± 4.80 | 0.3681 | – | 132.0 ± 7.09 | 111.2 ± 4.80 | < 0.0001 | [−26,39 to − 15,21] | |
LE | 118.47 ± 10.36 | 0.0420 | [−14,1 to −0,27] | |||||||
P100-Da 30 R Lob | Amplitude (μV) | RE | 8.29 ± 3.72 | 6.29 ± 2.16 | 0.1179 | – | 4.40 ± 1.56 | 6.29 ± 2.16 | 0.0319 | [0,1813 to 3,59] |
LE | 7.44 ± 3.91 | 0.3846 | – | |||||||
Latency (ms) | RE | 116.79 ± 6.21 | 112.12 ± 8.02 | 0.0588 | – | 134.7 ± 15.6 | 112.12 ± 8.02 | 0.0006 | [−34,03 to −10,97] | |
LE | 122.38 ± 13.51 | 0.0283 | [−19,5 to − 1,16] | |||||||
P100-Da 30 L Lob | Amplitude (μV) | RE | 7.94 ± 4.01 | 5.93 ± 2.01 | 0.1392 | – | 3.85 ± 1.44 | 5.93 ± 2.01 | 0.0128 | [0,494 to 3,66] |
LE | 6.48 ± 3.78 | 0.6649 | – | |||||||
Latency (ms) | RE | 117.14 ± 7.45 | 112.4 ± 7.32 | 0.0898 | – | 136.8 ± 22.4 | 112.4 ± 7.32 | 0.0039 | [−39,96 to −8,84] | |
LE | 122.93 ± 17.36 | 0.0724 | – |